Fortitude Family Office’s RAPT Therapeutics RAPT Stock Holding History

Fortitude Family Office’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-63	Closed	-$2.13K	–	2036
2025 Q4	$2.13K	Hold	63	–	–	﹤0.01%	1149
2025 Q3	$1.63K	Buy	+63	New	+$824	﹤0.01%	1339
2024 Q4	–	Sell	-120	Closed	-$1.93K	–	1366
2024 Q3	$1.93K	Buy	+120	New	+$2.43K	﹤0.01%	1013

Fortitude Family Office's RAPT Position: Q1 2026 in Review

Fortitude Family Office sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 63 shares — an estimated $2.13K sold.

Fortitude Family Office first reported a position in RAPT in Q3 2024 and held it in 3 quarters. The position peaked at $2.13K in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Fortitude Family Office reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Fortitude Family Office sold 63 RAPT Therapeutics shares in Q1 2026, an estimated $2.13K.
Fortitude Family Office first reported a position in RAPT Therapeutics in Q3 2024 and held it in 3 quarters.
Fortitude Family Office's RAPT Therapeutics position peaked at $2.13K in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.